The presence of cancer of the prostate does not mean that a patient will succumb to the disease. In fact, prior to the advent of prostate-specific antigen (PSA) testing, the cause of death in 50% of men with detectable extraglandular cancer was intercurrent disease. No studies have conclusively demonstrated a definitive benefit of surgery or radiation over simple observation; therefore treatment complications must absolutely be restricted to a bare minimum while demonstrating curative effect. This review presents a balanced perspective on the management of prostate cancer which results from non-adversarial, extensive, and continuous interactions between two very active Departments (Urology and Radiation Oncology). Such a multidisciplinary approach fosters relevant research projects and ultimately benefits patient care.
|Number of pages||12|
|State||Published - Jan 1 1994|
- prostate cancer
- radiotherapeutic approach
ASJC Scopus subject areas